-
Aprea Therapeutics NASDAQ:APRE Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53. The Company's lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Eprenetapopt has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA for MDS, Fast Track designation from the FDA for AML, and Orphan Drug designation from the European Commission for MDS, AML and ovarian cancer. APR-548, a next generation small molecule reactivator of mutant p53, is being developed for oral administration.
Location: | Website: www.aprea.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-13.26M
Cash
28.69M
Avg Qtr Burn
-3.39M
Short % of Float
0.26%
Insider Ownership
11.27%
Institutional Own.
42.17%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ATRN-119 Details Solid tumor/s, Cancer | Phase 1 Data readout | |
APR-1051 Details Solid tumor/s, Cancer | Phase 1 Data readout | |
Eprenetapopt (APR-246) + azacitidine Details Acute myeloid leukemia, Cancer, Myelodysplastic syndrome | Failed Discontinued | |
Eprenetapopt (APR-246) + Azacitidine Details Blood disorder, Myelodysplastic syndrome | Failed Discontinued | |
APR-548 + azacitidine Details Mutant Myelodysplastic Syndromes | Failed Discontinued |